Articles

The IRA will be measured not just by how much it can lower prices, but also by whether it continues to encourage drug makers to invest in new treatments.

Workplace absences, along with sales lost due to the cessation of brick-and-mortar retail shopping, airline travel and public gatherings, contributed the most.

The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.

Darius Lakdawalla was part of a panel of experts called upon by the U.S. House Ways and Means Subcommittee on Health.

The Centers for Medicare and Medicaid Services refuses to approve breakthrough drugs.

To make sure that CMS is getting its money’s worth for today’s drugs, it must ensure that the maximum fair price is aligned to drug value.

CMS should abandon CED or, at minimum, reform and restrict its use only for off-label applications of therapies.

We now have useful and valid alternatives that allow for the assessment and valuation of treatments that improve population health without discriminating against vulnerable patient populations.

USC Schaeffer white paper finds that increasing access to obesity treatments would help save lives and reduce healthcare costs.

Over 20 researchers cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations for the Medicare Drug Price Negotiation Program